Welcome to our dedicated page for Gossamer Bio news (Ticker: GOSS), a resource for investors and traders seeking the latest updates and insights on Gossamer Bio stock.
Gossamer Bio reports clinical, financial, and corporate updates tied to seralutinib, its investigational inhaled tyrosine kinase inhibitor for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Recurring developments include Phase 3 study results, regulatory pathway updates, collaboration activity with Chiesi Group, quarterly financial results, and capital allocation updates.
Company news also covers Nasdaq Rule 5635(c)(4) employment inducement grants under the 2023 Employment Inducement Incentive Award Plan, investor conference participation, and business development or resource-allocation actions related to its pulmonary hypertension strategy.
Gossamer Bio (NASDAQ:GOSS) reported early tender results for its exchange offer for 5.00% Convertible Senior Notes due 2027.
Holders tendered $181.052 million, or 90.526% of outstanding notes. The company lowered the minimum tender condition to 90.5% and expects early settlement on June 4, 2026, issuing new 7.50% secured notes and equity.
Gossamer Bio (NASDAQ:GOSS) extended the early tender date for its exchange offer and consent solicitation for 5.00% Convertible Senior Notes due 2027 to 5:00 p.m. ET on June 2, 2026.
Holders exchanging receive new 7.50% secured notes due 2030, equity securities, and, for early tenders, purchase warrants.
Gossamer Bio (NASDAQ:GOSS) launched an exchange offer and consent solicitation for its $200 million 5.00% Convertible Senior Notes due 2027, targeting elimination of over $120 million of debt with support from holders of approximately 75.2% of the notes.
Eligible institutional holders may exchange into new 7.50% first-lien convertible notes due 2030, common stock or prefunded warrants, and, for early tenders, additional purchase warrants. The offer runs through June 16, 2026, subject to a 98% minimum tender condition and other customary terms.
Gossamer Bio (Nasdaq:GOSS) reported Q1 2026 results and key updates on seralutinib for PAH. An in‑person FDA Pre‑NDA Type B meeting is scheduled for mid‑June, with a planned NDA submission in September 2026 and potential FDA decision in Q3 2027.
Exploratory PROSERA CT FRI data showed multiple nominally statistically significant multi‑compartment imaging effects correlated with clinical outcomes. Gossamer launched an exchange offer for its $200M 5.00% convertible notes, which upon full participation would cut convertible debt to $72M. Q1 cash was $99.2M, with runway into Q1 2027.
Gossamer Bio (Nasdaq:GOSS) will report its first quarter 2026 financial results on Monday, May 18, 2026. Management will host a live conference call and webcast at 8:00 a.m. ET to discuss results and provide a corporate update for investors.
Gossamer Bio (Nasdaq: GOSS) reported Q4 and full-year 2025 results, provided a corporate update, and outlined next steps after PROSERA Phase 3 topline data.
Key points: PROSERA narrowly missed its prespecified alpha at Week 24; prespecified higher‑risk and CTD‑PAH subgroups showed larger 6MWD gains. Enrollment in the PH‑ILD SERANATA study is paused. Year‑end cash and marketable securities were $136.9 million, funding operations into Q1 2027.
Gossamer Bio (Nasdaq: GOSS) reported topline Phase 3 PROSERA results for seralutinib in pulmonary arterial hypertension (PAH). The primary endpoint showed a placebo‑adjusted 6MWD improvement of +13.3 m at Week 24 (p=0.0320), missing the prespecified alpha of 0.025. Key secondary endpoints favored seralutinib, including a -120.4 ng/L NT‑proBNP reduction (p=0.0002). Prespecified intermediate/high‑risk patients (n=234) achieved a +20.0 m placebo‑adjusted 6MWD (p=0.0207). Safety was generally consistent with prior studies, though transaminase elevations ≥3x ULN occurred in 13% of seralutinib patients versus 1% placebo. Gossamer plans to meet the FDA and paused SERANATA enrollment to evaluate regional results.
Gossamer Bio (Nasdaq: GOSS) announced that its Compensation Committee approved an inducement grant of non‑qualified stock options to three non‑executive employees, effective January 5, 2026.
The awards cover an aggregate of 212,500 options with an exercise price of $2.74 per share (equal to the Jan 5, 2026 closing price), a 10‑year term, and vest over four years (25% at one year, then 36 monthly installments), subject to the 2023 Inducement Plan and individual option agreements.
Gossamer Bio (Nasdaq: GOSS) announced an inducement stock option grant approved by its Compensation Committee, effective December 5, 2025, to a newly hired non-executive employee under the 2023 Inducement Plan.
The award allows purchase of up to 200,000 common shares at an exercise price of $3.33 per share (the closing Nasdaq price on December 5, 2025). Options carry a 10-year term and vest over four years (25% after one year, then monthly over 36 months), subject to continued employment and plan terms.
Gossamer Bio (NASDAQ: GOSS) will participate in two investor conferences in December to discuss clinical progress and corporate strategy for seralutinib.
Piper Sandler 37th Annual Healthcare Conference: presentation and 1x1 meetings on December 2, 2025 at 9:00 AM ET in New York, NY. Oppenheimer Movers in Rare Disease Summit: panel and 1x1 meetings on December 11, 2025 at 9:00 AM ET in New York, NY.
Both events provide opportunities for investor Q&A on seralutinib development for PAH and PH-ILD.